UK Focused Ultrasound Foundation announces launch

Press releases may be edited for formatting or style | January 30, 2023 Business Affairs Ultrasound

UK FUSF is already partnering with the prostate cancer charity Prost8 UK and focused ultrasound device manufacturer Sonablate to increase access of focused ultrasound treatment for patients diagnosed with prostate cancer by co-funding the deployment early this year of a new prostate cancer treatment device at Guys & St Thomas' Hospital in London.

“I’ve been studying the use of focused ultrasound technology in oncology and have worked with the US Foundation for many years,” said Professor Gail ter Haar of The Institute of Cancer Research. “The launch of the UK FUSF is an incredibly important milestone. This organisation will further catalyse development and adoption of the technology, bringing much needed innovative new treatments to our community and beyond.”

The potential of focused ultrasound to be a game-changing treatment for so many diseases has attracted the attention of celebrities including musician Peter Gabriel, an honorary member of the UK FUSF Advisory Council. Said Mr. Gabriel, “Sound has been the stuff I work with every day of my life. It’s thrilling to see how powerful it can be when ingeniously applied to healthcare. I’m delighted to see these pioneering technologies take root in the UK.”


About the UK Focused Ultrasound Foundation
Together with our sister organisation in the US, the UK Focused Ultrasound Foundation is working to provide patients with this noninvasive, life-changing treatment option in the shortest time possible. The UK FUSF will contribute financial and human resources to foster collaboration, to build knowledge and to streamline the process and overcome barriers. Focused ultrasound research in the UK has been funded by the US Foundation since 2009.


About Focused Ultrasound
Focused ultrasound uses ultrasound energy guided by real-time imaging to treat tissue deep in the body without incisions or radiation. It is approved in the UK to treat prostate cancer and essential tremor. Dozens of additional indications are approved elsewhere in the world, including the United States, Europe and Asia. The technology is in various stages of research and development for nearly 170 diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, metastatic breast tumours, and tumours of the brain, liver and pancreas.

Back to HCB News

You Must Be Logged In To Post A Comment